RTP Mobile Logo
Select Publications

Azuma A, Kudoh S. High prevalence of drug-induced pneumonia in Japan. Nihon Kaika Gakkai Zasshi 2007;96(6):1077-82. Abstract

Gettinger S et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: Results from the CA209-003 study. J Clin Oncol 2018;36(17):1675-84. Abstract

Jänne PA, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov 2022;12(1): 74-89. Abstract

Johkoh T et al. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: A position paper from the Fleischner society. Radiology 2021;298(3):550-66. Abstract

Lee H et al. Transient asymptomatic pulmonary opacities during osimertinib treatment and its clinical implication. J Thorac Oncol 2018;13(8):1106-12. Abstract

Levy B et al. TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC. IASLC 2022;Abstract MA13.07.

Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9-20. Abstract

Noonan SA et al. Transient asymptomatic pulmonary opacities occurring during osimertinib treatment. J Thorac Oncol 2016;11(12):2253-8. Abstract

Powell CA. Pulmonary infiltrates in a patient with advanced melanoma. J Clin Oncol 2017;35(7):705-8. Abstract

Powell CA et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 2022;7(4):100554. Abstract

Skeoch S et al. Drug-induced interstitial lung disease: A systematic review. J Clin Med 2018;7(10):356. Abstract

Swain SM et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 2022;106:102378. Abstract